NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT07406633 2026-05-19KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line SettingKumquat Biosciences Inc.Phase 2 Recruiting46 enrolled